Skip to main content
SpringerLink
Log in

Sicca Syndromes

  • Chapter
  • First Online:
Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy

Abstract

Biologic agents that block immune checkpoints have significantly advanced cancer therapy. However, treatment with these agents frequently leads to inflammation in specific organ systems not necessarily affected by the cancer, including the salivary and lacrimal glands with resultant hypofunction. Collectively, these are termed “immune-related adverse events.” When the salivary and/or lacrimal glands are involved, this condition is referred to as immune checkpoint inhibitor-induced sicca (ICI-induced sicca). “Sicca syndrome” is a loosely defined entity that encompasses dryness of more than one mucosal surface, generally that of the eyes and mouth. We discuss the epidemiology and postulate on the pathogenesis of ICI-induced sicca. We then review the literature on ICI-induced sicca and detail the clinical findings from 89 reported cases. One defining feature of ICI-induced sicca is that the condition often develops abruptly and is objectively quite severe. Within the reported cases, we highlight marked clinical heterogeneity with three potential patient subsets: (i) those with de novo sicca without systemic symptoms, (ii) those with de novo sicca with systemic symptoms, and (iii) and those with a flare of a preexisting rheumatic disease with sicca. The clinical workup of ICI-induced sicca is described, including the engagement of multiple specialists, and a management algorithm for treating ICI-induced sicca. Despite the involvement of the activation of T cells and secretion of cytokines in the affected tissues, the pathophysiology underlying ICI-induced sicca remains poorly understood.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017;23:540–7.

    Article  CAS  PubMed  Google Scholar 

  3. Tison A, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71:2100–11.

    Article  CAS  PubMed  Google Scholar 

  4. Boutros C, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–86.

    Article  CAS  PubMed  Google Scholar 

  5. Hodi FS, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–92.

    Article  CAS  PubMed  Google Scholar 

  6. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17:610–6.

    Article  CAS  PubMed  Google Scholar 

  8. Moutsopoulos HM, et al. Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med. 1980;92:212–26.

    Article  CAS  PubMed  Google Scholar 

  9. Baer AN, et al. Rare diagnosis of IgG4-related systemic disease by lip biopsy in an international Sjögren syndrome registry. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e34–9.

    Article  PubMed  Google Scholar 

  10. Cappelli LC, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43–50.

    Article  CAS  PubMed  Google Scholar 

  11. Haslam A, Prasad V. Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    Article  PubMed  Google Scholar 

  13. Hammers HJ, et al. Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35:3851–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hellmann MD, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–31.

    Article  CAS  PubMed  Google Scholar 

  15. Robert C, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.

    Article  CAS  PubMed  Google Scholar 

  16. Long GV, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202–10.

    Article  CAS  PubMed  Google Scholar 

  17. Motzer RJ, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430–7.

    Article  CAS  PubMed  Google Scholar 

  18. Giaccone G, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347–55.

    Article  CAS  PubMed  Google Scholar 

  19. Ramos-Casals M, et al. Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the international Immuno Cancer registry (ICIR). Clin Exp Rheumatol. 2019;37(Suppl 118):114–22.

    PubMed  Google Scholar 

  20. Abdel-Rahman O, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17:387–94.

    Article  CAS  PubMed  Google Scholar 

  21. Iwama S, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.

    Article  PubMed  CAS  Google Scholar 

  22. Mammen AL, et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 2019;78:150–2.

    Article  CAS  PubMed  Google Scholar 

  23. Johnson DB, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019;25:1243–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hua C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016;152:45–7.

    Article  PubMed  Google Scholar 

  25. Attia P, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti–cytotoxic T-lymphocyte Antigen-4. JCO. 2005;23:6043–53.

    Article  CAS  Google Scholar 

  26. Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010;89:1016–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schönrich G, Raftery MJ. The PD-1/PD-L1 Axis and virus infections: a delicate balance. Front Cell Infect Microbiol. 2019;9:1593–14.

    Article  CAS  Google Scholar 

  29. Chen J, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Warner BM, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24:1259–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ortiz Brugués A, et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist. 2019-0467-5. 2019; https://doi.org/10.1634/theoncologist.2019-0467.

  32. Pringle S, et al. Lack of conventional acinar cells in parotid salivary gland of patient taking an anti-PD-L1 immune checkpoint inhibitor. Front Oncol. 2020;10:420.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis. Respirol Case Rep. 2018;6:e00322.

    PubMed  PubMed Central  Google Scholar 

  34. Ghosn J, et al. A severe case of neuro-Sjögren's syndrome induced by pembrolizumab. J Immunother Cancer. 2018;6:110.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Narváez J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev. 2018;17:1040–5.

    Article  PubMed  CAS  Google Scholar 

  36. Burbelo PD, et al. Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res. 2019;98:772–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Smith MH, Bass AR. Arthritis after Cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res(Hoboken). 2018;71:362–6.

    Article  CAS  Google Scholar 

  38. Le Burel S, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-Centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44.

    Article  PubMed  CAS  Google Scholar 

  39. Nguyen AT, Elia M, Materin MA, Sznol M, Chow J. Cyclosporine for dry eye associated with Nivolumab: a case progressing to corneal perforation. Cornea. 2016;35:399–401.

    Article  PubMed  Google Scholar 

  40. Acero Brand FZ, et al. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer. 2018;6:22.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kim J, et al. A validated method of labial minor salivary gland biopsy for the diagnosis of Sjögren's syndrome. Laryngoscope. 2016;126:2041–6.

    Article  PubMed  Google Scholar 

  42. Rajan A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Warner B, Baer A. In Reply. The Oncologist. 2019-0515-2. 2019; https://doi.org/10.1634/theoncologist.2019-0515.

  44. Eigentler TK, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.

    Article  CAS  PubMed  Google Scholar 

  45. Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2018;14:247–9.

    Article  PubMed  Google Scholar 

  46. Richter MD, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71:468–75.

    Article  CAS  PubMed  Google Scholar 

  47. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904–11.

    Article  PubMed  Google Scholar 

  48. Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3:e000412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Teyssonneau D, Cousin S, Italiano A. Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Ann Oncol. 2017;28:3108.

    Article  CAS  PubMed  Google Scholar 

  50. Noble CW, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2019;21:1–6.

    Google Scholar 

  51. Zimmer L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25.

    Article  CAS  PubMed  Google Scholar 

  52. Leipe J, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4:e000714.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Le Burel S, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis. 2018;77:468–70.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Institute of Dental and Craniofacial Research Division of Intramural Research. We would like to thank Dr. Peter Burbelo for this thoughtful editing of the manuscript. We acknowledge and thank the clinical support team of the National Institute of Dental and Craniofacial Research Sjögren’s Syndrome Clinic for their organization of the patient visits and data collection. We thank the oncologists at Johns Hopkins Medical Institute and the NIH National Cancer Institute Center for Cancer Research for the referral of patients and active collaborations. Lastly, we thank the participation of our subjects in the research protocols. It is only through partnerships with patients that clinical research progress can be made.

Author information

Authors and Affiliations

  1. Salivary Disorders Unit, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA

    Blake M. Warner

  2. Sjögren’s Syndrome Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA

    Blake M. Warner

  3. Sjögren’s Syndrome Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA

    Alan N. Baer

  4. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Alan N. Baer

Authors
  1. Blake M. Warner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan N. Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Blake M. Warner .

Editor information

Editors and Affiliations

  1. Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Maria E. Suarez-Almazor

  2. Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

    Leonard H. Calabrese

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Warner, B.M., Baer, A.N. (2021). Sicca Syndromes. In: Suarez-Almazor, M.E., Calabrese, L.H. (eds) Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-56824-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56824-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56823-8

  • Online ISBN: 978-3-030-56824-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation